Canadian Journal of Gastroenterology and Hepatology
Volume 2019 (2019), Article ID 5380815, 9 pages
https://doi.org/10.1155/2019/5380815

Review Article

Roles of Steroids in Preventing Esophageal Stricture after Endoscopic Resection

Yu Qiu1,2 and Ruihua Shi1,2

¹Medical School of Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, China
²Department of Gastroenterology, Zhongda Hospital, Medical School of Southeast University, No. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, China

Correspondence should be addressed to Ruihua Shi; ruihuashi@126.com

Received 30 January 2019; Revised 20 February 2019; Accepted 7 March 2019; Published 1 April 2019

Academic Editor: Toshio Uraoka

Copyright © 2019 Yu Qiu and Ruihua Shi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Background and Purposes. Endoscopic resection has been worldwide recognized as a treatment strategy for early esophageal lesions. The occurrence of esophageal stricture after endoscopic resection will reduce the quality of life of patients. This study will evaluate the efficacy and safety of steroids in the prevention of esophageal stricture after endoscopic resection and the influence of different steroid administration methods. Methods. In the relevant literature database, literature from 2008 to 2018 is retrieved by using preset keywords, the search results are carefully screened, and the conclusion of the literature is synthesized to form arguments and draw conclusions. Results. 73 articles met our requirements. Oral steroid administration, not prophylactic endoscopic balloon dilation alone, was effective in preventing esophagostenosis after esophagoscopic treatment and reducing the number of repeated endoscopic balloon dilations even after extensive endoscopic resection. Local steroid injection is useful and economy for preventing esophageal stricture, even though it may raise the risk of perforation during dilations. A wider range of circumferential mucosal defects is an independent predictor for stricture formation for patents given preventive steroid injections after endoscopic submucosal dissection. For complete circular mucosal defect, the further researches are essential to investigate the role of local steroid injection. The effect of other methods such as steroid gel, intravenous infusion of steroid, and novel steroid filling methods require more confirmation. Conclusions. Therefore, steroids play an irreplaceable role in preventing esophageal stricture after endoscopic resection. Oral and local injections of steroids are the two most acceptable methods and more prospective studies are needed to compare the effectiveness and safety of these two methods.

1. Introduction

Endoscopic resection has been worldwide recognized as a proper strategy for superficial esophageal dysplasia and carcinoma due to its feature of minimal invasion. As an alternative to esophagectomy, endoscopic mucosal resection (EMR) had been originally applied in the treatment for localized neoplasm, because of the better quality of life after surgery. Segmental circumcision of esophageal intima can successfully remove most of the stenosis lesions [1, 2]. However, the operation of segmental circumcision is easy to cause the relapse of superficial esophageal cancer (SEC) [3, 4]. In the past few years, focus of EMR has been gradually replaced by endoscopic submucosal dissection (ESD) for SEC. ESD allows the entire resection of the lesion regardless of its size and has a lower recurrence rate compared to EMR [5].

The incidence of esophageal stricture after endoscopic mucosal resection is rather high; patients often have to undergo radiofrequency ablation again to eliminate proliferative mucosa [6]. The definition of esophageal stenosis is a narrowing of the esophageal lumen found on endoscopy, which cannot be passed by a standard endoscope or is related to dysphagia [7]. The stricture rates after EMR are 1.3%-4.9% and 3%-11.6% for ESD [8, 9], but the comparability of these rates is low, because the circular extent of the mucosal defect differs among the studies. Chikatoshi et al.’s research found that extensive defect of esophageal mucosa is one of the important predictors of esophageal stricture after ESD [10], which has been verified by many other authors [11, 12]. In addition, Satoshi et al. added that T1A m2 histological depth was another important factor related to post-ESD esophageal stenosis [13].

The process of esophageal healing and stricture formation after endoscopic resection involves three stages: the first stage is an injury of epithelium, resulting in the damage of the barrier of the epithelial and making the submucosal layers exposed to food boluses, acid, or bile reflux and esophageal fungal or bacterial flora. The second stage is the activation of immune system [14] which is characterised by the hyperplasia of granulation tissue, including inflammatory cell infiltration and angiogenesis [15]. The third stage is scar tissue formation, which involves fibroblastic and myofibroblastic proliferation with the stimulation of cytokines like TNF-a, TGF-b1, IL-6, IL-1, IL-17A, PDGF, and so on [16].

Most post-ESD strictures are refractory and repeated endoscopic dilations are required [17]. Endoscopic dilation is effective for stricture of internal diameter after endoscopic esophageal mucosal dissection, but there is a high rate of recurrence [18]. Besides, repeated endoscopic balloon dilations (EBDs) would give rise to complications including perforation and bleeding [19]. It is reported that 7.1-9% of the patients suffer from perforation after repeated endoscopic dilation [20]. In recent years, there are many treatments for esophageal stricture after esophageal mucosal exfoliation, such as stents placement, botulinum toxin injection, oral tranilast, and local autologous cell transplantation. Numerous studies have shown good therapeutic effects, while more larger multicenters investigations are required. Therefore, prevention of esophageal stenosis after endoscopic resection is necessary for endoscopic therapy to develop.

Due to the double function of anti-inflammation, treatment of esophageal stricture by oral or local steroid injection has become the preferred option [21]. This review aims to evaluate the efficacy and safety of steroids in the prevention of esophageal stricture after endoscopic resection and evaluate the efficacy of steroids in different routes of administration.

2. Methods

We searched the relevant literature on PubMed and Web of Science (from 2008 to December 2018) that focused on steroid therapy for the prevention of esophageal stenosis after extensive endoscopic resections. The search terms included “esophageal stenosis or stricture” and “steroid” and animal studies were excluded from all literature. In addition, prevention was used as the criterion for research purposes, and treatment goals were excluded. As is seen from references, 73 articles eventually met our requirements.

2.1. Oral Steroid Method

Naoyuki et al. conducted a large number of clinical trials, which proved for the first time that oral steroids have a good therapeutic effect on esophageal stricture after esophageal mucosal stripping [22]. In the study, patients were given prednisolone 30 mg daily from the third day after ESD, and the dosage of prednisolone decreased by 5 mg per week until the end of the eighth week of the experiment. This study included 41 patients treated with ESD, whose circumference was more than three-quarters. The incidence of esophageal stricture in oral prednisolone group (5.3%) was significantly lower than that in pre-EBD group (31.8%, P=0.03). The average number of times requiring EBD treatment was 1.7 in the oral prednisolone group and 15.6 in the pre-EBD group (P < 0.0001). Later, Mikinori et al. [23] and Hiroki et al. [24] investigated oral steroid for prevention of esophageal stenosis by applying the Yamaguchi protocol with little change. It is worth mentioning that Hiroki et al. [24] paid attention to complete circumferential ESD, which showed that stenosis after ESD occurred in all patients. However, compared with EBD alone, the number of patients requiring EBD after steroid therapy was significantly reduced (13.8 versus 33.5, P < 0.001) and shorter than the period of physical rehabilitation (4.8 versus 14.2 months, P<0.005). Besides, some other investigations stated that oral corticosteroids can prevent esophageal stenosis after esophageal ESD [25–29]. Recently, in a survey conducted by Iizuka et al., 22 post-ESD patients requiring EBD treatment were included [25]. They investigated a modified oral steroid administration: in the first three weeks, 30 mg prednisolone was given orally every day, and the dosage of prednisolone was reduced by 5 mg every three weeks. The results showed that the esophageal stricture rate (36.4%) in the modified group was significantly lower than that in the original group (82%, P=0.04) after ESD compared with the traditional 8-week decreasing regimen. In the improved group, the number of patients requiring EBD treatment also decreased significantly (6.2 versus 19.4, P=0.023). Therefore, compared with previous methods, this improved administration is exciting in preventing esophageal stricture after endoscopic surgery.

Current studies have fully confirmed the preventive and therapeutic effects of steroids on esophageal stricture after esophageal endometrectomy, but more studies are needed to determine the safest and most effective way of administration, dosage, and time of administration. As we can see from Table 1, most investigations adopt 8-week therapy despite the differentiation of dose and interval. However, the total dose of prednisolone usually exceeds 1,000 mg in eight weeks and it has been reported that patients undergoing systemic steroid administration for 21 days or taking more than 700 mg prednisolone have a raised risk of infection [30]. Oliveira et al. confirmed that the use of high dose glucocorticoids would lead to serious complications such as gastrointestinal ulcer, elevated blood sugar, immunosuppression, osteoporosis, and even systemic infection [31]. For example, pneumocystis pneumonia (PCP) is caused by systemic immune suppression in some patients who take high doses of steroids for a long time. The mortality rate of PCP is very high [32]. Limper et al. suggested that steroids administration in doses greater than 20 mg for 1 month or longer should call for prophylaxis for PCP [33]. In addition, Tsukasa et al. reported an 85-year-old man who had almost completely resected the periphery of esophageal mucosa and used steroids to prevent esophageal stricture after surgery [34]. After six weeks’ steroid treatment with a total of 1120 mg prednisolone, he developed high fever and finally was diagnosed with infection of nocardiosis. These cases suggest the importance and necessity of preventing fatal infections in patients receiving systemic steroid treatment after endoscopic resection and it is necessary to reduce the amount and shorten the duration of systemic steroid therapy. Stuck et al. pointed out that the early application of steroids after esophageal mucosal resection is helpful to cut off the inflammation process as early as possible, and patients will get more benefits [35]. Hiroki et al.’s study compared the occurrence and progression of esophageal stricture after early and late steroid therapy for ESD [24]. In their study, three patients in EBD therapy alone group finally orally intake prednisolone after about 158 days due to the fact that they failed to responded to EBD therapy alone. Therefore, they added a subgroup analysis to compare these three additional patients with 10 original patients in the steroid plus EBD group. The results showed that the time needed for EBD in steroid + EBD group was significantly reduced (13.8 versus 46.0, P < 0.002), and the total EBD time was significantly shortened (4.8 versus 17.5, P<0.005). 3-7 days after injury is the key period for collagen deposition and fibrosis, which may be the main mechanism for the early benefit of steroid hormone application [36]. More studies with larger sample size comparing early and late oral steroid therapy are needed to confirm and further explain the results of the study and explore the mechanism of steroids exerting local anti-inflammatory and antifibrotic effects. To conclude, early oral steroid administration, with proper amount and duration, not preventive EBD alone, was effective in preventing esophageal stricture and avoiding EBD. Further larger scale of investigations are required before this therapeutic option can be widespread.

Table 1: Clinical outcomes of oral steroid method of preventing esophageal stricture after endoscopic resection.

Author, year
Design
Setting
Sample size
(treated/control)
Follow-up
Stricture rate
Mean or median number of EBD
Adverse event

Lizuka, 2018 [25]
Retrospective cohort study
ESD
100%
SEC
11/11
Gastroscopy: 1, 4, 8, 12, 16, and 20 weeks after ESD
36.4%VS 82%
(P=0.04)
6.2 VS 19.4
(P=0.023)
8 VS 3
(P=0.043)

Zhou, 2017 [26]
Retrospective cohort study
ESD
>75%
ESCC
13/10
Gastroscopy: 1, 3, 6, and 12 months after ESD
23.1%VS 80%
(P=0.007)
0.69 VS 13.5
(P=0.004)
None

Jean-Philippe,2017 [27]
Single-center retrospective study
EMR
>50%
Barrett’s esophagus
29/0
Gastroscopy: 2, 6, 12, and 24 months after EMR
13%
2
None

Mikinori, 2015[23]

Retrospective cohort study
ESD
>75%
ESCC
17/16
Gastroscopy: 8 weeks after ESD
17. 6%VS
68.7%
P<0.01
4.6 VS 8.1
P<0.01
None

Hiroki, 2013 [24]
Retrospective cohort study
ESD
100%
SEC
10/13
Gastroscopy: 7 days, 2-, 3-, and 4-week interval until week after negative endoscopy
Both 100%
13.8 VS 33.5
P<0.001
None

Naoyuki, 2011 [28]
Case report
ESD
100%
ESCC
1/0
Gastroscopy: 1, 3, and 6 months after ESD
0%
0
None

Hajime, 2011 [29]
Retrospective study
ESD
100%
ESCC
4/3
Gastroscopy: 3, 6, and 12 months after ESD and then annually thereafter
Both 100%
3.25 VS 32.67
(P<0.05)
None

Naoyuki, 2011 [22]
Retrospective study
ESD
>75%
ESCC
19/22
Gastroscopy: 1, 3, 6, and 12 months after ESD and then annually thereafter
5.3%VS31.8%
(P=0. 03)
1.7 VS 15.6
(P<0. 0001)
None

SEC, superficial esophageal cancer; ESCC, esophageal squamous cell carcinomas.

2.2. Local Steroid Injection

Holder et al. [37, 38] took the lead in studying the effect of corticosteroid local injection therapy on benign esophageal stricture in dogs and children. Since then, its clinical application has gradually increased [39–41]. In recent years, local steroid injection therapy has been widely used to prevent the formation of stenosis after SEC [7, 42]. Kouichi et al. had explored the healing process of local ulcers after ESD by injecting steroids into pigs’ esophagus [43]. After Satoru’s study, they used triamcinolone acetonide at doses and injection intervals [7]. What the conclusion they drew was that local steroid injection seemed to be effective to prevent the stricture after esophageal ESD, but as for the optimal injection technique, frequency, and dose of triamcinolone, it requires further people-based studies. As is shown in Table 2, several prospective or retrospective studies have manifested that local steroid injection at the ulcer base significantly reduced esophageal stricture rate after endoscopic resection.

Table 2: Clinical outcomes of local steroid injection of preventing esophageal stricture after endoscopic resection.

Author, year
Design
Setting
Sample size
(treated/control)
Follow-up
Stricture rate
Mean or median number of EBD
Adverse event

Tsujii, 2017 [50]
Retrospective study
ESD>75%
SENs
28/10
Gastroscopy: a few months after ESD
43% VS 90% (P=0.012)
8 VS 5
(P>0.05)
5 VS 1

Yasuaki, 2017 [52]
Retrospective study
ESD>2/3but
<100%
SENs
37/37
Gastroscopy: every 4 weeks after ESD or receiving complaints of dysphagia
18.9% VS 45.9%
(P=0. 016)
0.6±1.5 VS
2.8±4.6
(P<0.01)
None

Furuhashi, 2017 [53]
Historical control study
ESD≥30mm diameter or ≥3/4
43/25
Not mentioned
Multivariate analysis: OR:0.041,95%CI:0.007 to 0.24, p<0.001
2.3 VS 10.9
None

Xu, 2016 [46]
Randomized controlled trial
ESD≥1/2
SENs
17/23
Not mentioned
29.4% VS 69.6%
(P=0.02)
0.5 VS 1.3
(P=0.16)
1 VS 0

Yoshiki, 2016 [49]
Retrospective study
ESD>1/2
SENs
30/15
Not mentioned
40% VS 60%
(P>0.05)
Not significantly different
6 VS 0

Yasuaki, 2016 [47]
Retrospective study
>2/3but<3/4
ESCC
28/28
Gastroscopy: 4 and 8 weeks after the treatment.
10.7% VS 35.7%
(P=0.035)
Not mentioned
Not mentioned

Takahashi, 2015 [45]
Prospective study
ESD>75%
ESCC
16/16
Not mentioned
62.5% VS 87.5%
(P=0. 22)
6.1 VS 12.5
(P=0.04)
1.0% VS 0. 5%

Lee, 2013 [66]
Case report
ESD 100%
ESCC
1/0
Gastroscopy: 2 and 4 weeks and 4 months after ESD. Total follow-up time lasts for 6 months.
0%
0
None

Hanaoka, 2012 [44]
Prospective study
ESD>75% but<100%
ESCC
30/29
Gastroscopy: whenever patients reported dysphagia and 2 months after ESD in patients without dysphagia.
10% VS 66%
(P<0.0001)
0 VS 2
(P<0.0001)
2 VS 0

Satoru,2011 [7]
Retrospective
ESD
>75%
ESCC
21/20
Gastroscopy: assess for stenosis at 1
week, 1 month, 6 months, and 1 year after ETI.
19% VS 75%
(P<0.001)
1.7 VS 6.6
(P<0.001)
None

SENs, superficial esophageal neoplasms; LSI, local steroid injection; DSP, dexamethasone sodium phosphate; TA, triamcinolone acetonide; TTI, topical triamcinolone injection; ESCC, esophageal squamous cell carcinoma.

Satoru et al. [7] conducted the first study to manifest that endoscopic triamcinolone injection (ETI) leads to decreased stricture rate and numbers of EBD in patients undergoing ESD for SEC in 2011. Based on the knowledge that fibroblasts begin to proliferate 3 to 7 days after local trauma[36], they began ETI at this time point and injected steroid hormones into the site of ulcer. The results showed that when triamcinolone acetonide was injected into the shallow layer with equal interval of 2 mg, the total dose of triamcinolone acetonide was 18-62 mg; there were no significant complications such as delayed perforation and local abscess. Then Hanaoka et al. [44] conducted a prospective study on 30 patients with esophageal squamous cell carcinoma (ESCC) treated with EDS which had a periesophageal defect of more than 3/4, but not a whole-week defect. Compared with 29 patients without ETI treatment, the rate of esophageal stricture in the experimental group was significantly reduced (10% versus 66%, P<0.0001), and the number of patients requiring EBD treatment in the later stage was significantly reduced (0-2 versus 0-15, P<0.0001). One patient in study group suffered from a submucosal tear and another suffered from bleeding, which were both not direct results of EBD. In addition, for patients with whole circumferential mucosal defects after esophageal ESD, Takahashi et al. [45] conducted a randomized controlled trial and they found that ETI did not reduce the stricture rate, but decreased the mean times of dilatation sessions (from 12.5 to 6.1), indicating that, in some patients, local steroid injection prevented the rapid healing of esophageal ulcer. Similarly, the results of a single-center randomized controlled trial conducted by Mei-Dong Xu et al. [46] showed that local steroid hormone injection was effective in preventing stenosis in patients with peripheral esophageal defects less than half a week after ESD. Yasuaki et al.’s [47] propensity score matching analysis excluded steroid injection selection bias and other confusing factors. They used two LSI methods: one was to inject 80 mg triamcinolone acetonide (TA) immediately after ESD; the other was to inject 6.6 mg dexamethasone and Twi immediately after ESD. Stenosis was found in 1 of 12 lesions treated with TA (8.3%) and in 2 of 16 lesions treated with dexamethasone (12.5%) (p = 1.00). Their results also indicated that LSI is usefully limited to mucosal defects less than 3/4 of their esophageal circumference. Therefore, what on earth are the risk factors for stricture formation in patients who received ETI after esophageal ESD? Recently, a study by Yasuaki et al. [48] assessed the risk factors for preventing esophageal stricture by routine prophylactic steroid injection after ESD. They concluded that a wide mucosal defect (odds ratio: 2.42; 95% confidence interval: 1.01-5.80; P=0.048) was an independent predictor of stenosis. The cut-off value related to stenosis formation was 5/6 of the peripheral mucosal defect. Tendency analysis showed that the rate of esophageal stricture was increased in patients with circumference greater than 5/6, compared with those with less than 5/6 mucosal defects (odds ratio: 5.70; 95% confidence interval: 1. 61-20.18; P= 0.007).

Yoshiki et al. [49] stated that the boundary between esophageal submucosa and muscular layer was blurred and the muscular layer was partially ruptured after local steroid injection. Thereafter, Yoshiki’s team conducted a central retrospective study to assess the prognosis of patients with periesophageal mucosal defects more than three-quarters of the time after ESD. Their findings found that 43% of LSI patients had esophageal stricture, compared with 90% of nonpreventive patients, and only esophageal perforation occurred in LSI patients [50]. Yamashina et al. [51] reported the cases of delayed perforation caused by tissue damage caused by LSI. They believed that injection needles should be avoided to puncture the intrinsic muscles directly. Therefore, mild puncture of the residual submucosa should be performed without needling deeper. EBD should also be performed cautiously. Regarding the amount of steroids injected, studies from Yasuaki [52] showed that a single dose of 80 mg TA had sufficient protection against stenosis, although this dose was lower than previous studies. Finally, according to the statistical data of Furuhashi et al. [53], each case in LSI group used 60±28 mg of triamcinolone acetonide and the Japanese public insurance system proposed a reduction of $9330 in medical expenses. In conclusion, LSI is useful and economical in preventing esophageal stricture after ESD, although it may increase the risk of perforation during EBD. A wide mucosal defect was an independent predictor of stenosis after LSI and the cut-off value was 5/6 of the peripheral mucosal defect. For complete circular ESD, more prospective studies are needed to investigate the role of LSI.

2.3. Other Methods Using Steroids

In addition to oral intake and local injection, steroids can also be applied in other forms such as sterid gel, intravenous drip infusion, and TA filling method to prevent esophageal stricture after ESD. In 2013, Hirohito Mori et al. [54] reported an innovative method using combined steroid gel application and balloon dilatation to prevent esophageal strictures after ESD, compared with steroid injection. They drew a conclusion that steroid gel application is more effective than local injection in terms of prevention of esophageal stricture after ESD. However, the results of Hirohito Mori’s study which was questioned by Yang Fan et al. [55] have made great contributions in optimizing and expanding the design process, data analysis, and results study of the experiment in this direction. In addition, Satoshi et al. [56] reported intravenous steroid infusion for the first time in 2010 as a case report. A 61-year-old male patient with SEC underwent esophageal ESD examination and treatment. Multiple myeloma and multiple bone metastases were found during further treatment. Therefore, from the 9th day after ESD, 40 mg dexamethasone was orally administered daily for three consecutive days, a total of three courses of treatment. Subsequently, the patient received peripheral blood stem cell transplantation, which was successful. During follow-up, no significant esophageal stricture or typical symptoms were found in this patient. This study opens a new era of pulsed hormone therapy. In 2015, Nakamura et al. [57] prospectively studied the efficacy and safety of steroid pulse therapy in preventing esophageal stricture after ESD. Esophageal cancer was diagnosed. No serious life-threatening complications related to steroid pulse therapy have been found. The median interval between ESD and EBD was 18 days (15-21 days) and 2 days (1-6 days). Although the occurrence of esophageal stricture seems inevitable, pulsed steroid regimens can significantly reduce the frequency and overall time of EBD. Similarly, Nakamura et al. [58, 59] conducted a prospective study of 11 patients in 2017 and found that pulsed steroid regimens were extremely safe. Unfortunately, no preventive effect on esophageal stricture was found. On this basis, they proposed a local esophageal tamponade therapy using triamcinolone acetonide (TA), which is to inject TA saline solution into the esophagus for a period of time, expecting the drug to penetrate evenly into the broader resected surface. The results showed that esophageal stricture was effectively controlled in all patients. Unfortunately, the results of large-scale data analysis are still lacking in this study.

3. Discussion

Wound healing is a process involving inflammation, hyperplasia, and remodeling, and scar formation is considered to be a part of wound healing. Collagen is the major fibrous connective tissue protein in scars [40]. In theory, steroids are the most suitable treatment agent for scar because they can inhibit inflammation response, collagen synthesis and fibroblast proliferation [60]. At present, oral or local steroid injection has become a common clinical treatment to prevent esophageal stricture after ESD. Compared with EBD, the treatment results are more economical and effective, and patients suffer less pain [51]. However, there are high-risk complications such as delayed ulcer healing, ulcer, or perforation caused by injection injury in LSI treatment. The oral steroid hormone pathway is not 100% safe. Severe complications such as immunosuppression, pulmonary infection, elevated blood sugar, osteoporosis, and mental disorders often occur. Tsukasa et al. reported a case of severe disseminated nocardiosis during oral steroid therapy [34]. Wang et al. made a meta-analysis with the objectives to evaluate the efficacy of steroids in preventing esophageal stricture after ESD and to conclude that LSI is superior to oral steroids in reducing EBD [61]. Recently, Yang et al. conducted another network meta-analysis to assess the efficacy and safety of different steroid applications in the prevention of esophageal stricture after endoscopic submucosal dissection [62]. Interestingly, they drew the conclusion that long-term oral steroid (at least 12-week period with more than 1470-mg prednisolone) might be the superior prevention for postoperative stricture with satisfying efficacy, comparing with preemptive EBD, median-term oral steroid, short-term oral steroid, and steroid injection therapy. However, it has been reported that patients undergoing systemic steroid administration for 21 days or taking more than 700 mg prednisolone have a raised risk of infection [30]. Therefore, more prospective comparative studies are needed to clarify the effectiveness and safety of oral steroid and local injection methods.

Multicenter prospective randomized controlled trials (JCOG1217) are currently comparing the efficacy of prophylactic oral steroids and LSI in the treatment of noncircular lesions [63]. Besides, Kawaguchi et al. [64] proposed a combined therapy called “sequential steroid therapy”, which means LSI of triamcinolone on the day of ESD followed by oral intake of prednisolone for the next few days. The effectiveness of this novel therapy requires confirmation by more prospective studies. According to a retrospective study conducted by Kadota et al. [65], stricture rates were assessed based on different widths of mucosal defects caused by ESD. Their findings confirm that prophylactic steroid use is effective in the treatment of esophageal stricture in patients with mucosal defect 7/8 weeks or more after ESD, but ineffective after full-week mucosal defect. Further investigations with larger sample size are required. In addition, more and more researchers take steroid therapy, either oral steroids or LSI, as a basic therapy for preventing esophageal stricture after ESD, combining with some other methods like stents insertion and polyglycolic acid sheets, which may have additive or synergistic effects. Nowadays, new methods for prevention and treatment of esophageal stricture after ESD have been widely studied, such as esophageal stent implantation, polyglycolic acid shielding, autologous oral epithelial cell transplantation, and so on. Many new methods have good results and broad prospects for clinical application, but large-scale studies are still needed to obtain more clinical data.

4. Conclusions

Steroids play an irreplaceable role in preventing stenosis after esophageal ESD. Its usage mainly includes oral steroid method, local steroid injection method, other methods such as steroid gel, intravenous infusion of steroid, and novel steroid filling methods. Currently the most widely accepted methods are oral steroid and LSI, and both of them have advantages and disadvantages; more researches are needed to compare the effectiveness and safety of these two methods. Early oral steroid administration, with proper amount and duration, not preventive EBD alone, was effective in preventing esophageal stricture and avoiding EBD. LSI is useful and economical in preventing esophageal stricture after ESD. A wide mucosal defect was an independent predictor of stenosis after LSI and the cut-off value was 5/6 of the peripheral mucosal defect. For complete circular ESD, more prospective studies are needed to investigate the role of LSI. Besides, a combination of these two methods, called sequential therapy, is a novel therapy requiring confirmation by more prospective studies. Last but not least, steroid therapy combining with other treatments like stents insertion and polyglycolic acid sheets may have additive or synergistic effects on the prevention of esophageal stricture after ESD.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors are profoundly grateful to the supervisor Ruihua Shi whose illuminating instruction and expert advice have guided them through every step of their writing of this thesis. He gave them lots of inspirations and encouragement.

References

M. Conio, D. A. Fisher, S. Blanchi, C. Ruggeri, R. Filiberti, and P. D. Siersema, “One-step circumferential endoscopic mucosal cap resection of Barrett's esophagus with early neoplasia,” Clinics and Research in Hepatology and Gastroenterology, vol. 38, no. 1, pp. 81–91, 2014.

G. W. Falk and G. G. Ginsberg, “Cutting to the chase: Circumferential endoscopic mucosal resection for Barrett's neoplasia,” Gut, vol. 59, no. 9, pp. 1163-1164, 2010.

O. Pech, A. Behrens, A. May et al., “Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus,” Gut, vol. 57, no. 9, pp. 1200–1206, 2008.

R. Ishihara, H. Iishi, Y. Takeuchi et al., “Local recurrence of large squamous-cell carcinoma of the esophagus after endoscopic resection,” Gastrointestinal Endoscopy, vol. 67, no. 6, pp. 799–804, 2008.

R. Ishihara, H. Iishi, N. Uedo et al., “Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan,” Gastrointestinal Endoscopy, vol. 68, no. 6, pp. 1066–1072, 2008.

M. Barret, B. Beye, S. Leblanc et al., “Systematic review: the prevention of oesophageal stricture after endoscopic resection,” Alimentary Pharmacology & Therapeutics, vol. 42, no. 1, pp. 20–39, 2015.

S. Hashimoto, M. Kobayashi, M. Takeuchi, Y. Sato, R. Narisawa, and Y. Aoyagi, “The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection,” Gastrointestinal Endoscopy, vol. 74, no. 6, pp. 1389–1393, 2011.

O. Pech, A. May, H. Manner et al., “Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus,” Gastroenterology, vol. 146, no. 3, pp. 652–660, 2014.

J. S. Kim, B.-W. Kim, and I.-S. Shin, “Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: a meta-analysis,” Digestive Diseases and Sciences, vol. 59, no. 8, pp. 1862–1869, 2014.

C. Katada, M. Muto, T. Manabe, N. Boku, A. Ohtsu, and S. Yoshida, “Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions,” Gastrointestinal Endoscopy, vol. 57, no. 2, pp. 165–169, 2003.

F. G. I. Van Vilsteren, R. E. Pouw, S. Seewald et al., “Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer:a multicentre randomised trial,” Gut, vol. 60, pp. 765–773, 2011.

Q. Shi, H. Ju, L. Q. Yao et al., “Risk factors for postoperative stricture after endoscopic submucosal dissection for superficial esophageal carcinoma,” Endoscopy, vol. 46, pp. 640–644, 2014.

S. Ono, M. Fujishiro, K. Niimi et al., “Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms,” Gastrointestinal Endoscopy, vol. 70, no. 5, pp. 860–866, 2009.

G. Wick, C. Grundtman, C. Mayerl et al., “The immunology of fibrosis,” Annual Review of Immunology, vol. 31, pp. 107–135, 2013.

M. Barret, F. Batteux, F. Beuvon et al., “N-acetylcysteine for the prevention of stricture after circumferential endoscopic submucosal dissection of the esophagus:a randomized trial in a porcine model,” Fibrogenesis Tissue Repair, vol. 5, no. 8, 2012.

J. S. Duffield, M. Lupher, V. J. Thannickal, and T. A. Wynn, “Host responses in tissue repair and fibrosis,” Annual Review of Pathology: Mechanisms of Disease, vol. 8, pp. 241–276, 2013.

J. Wen, Z. Lu, and Q. Liu, “Prevention and treatment of esophageal stenosis after endoscopic submucosal dissection for early esophageal cancer,” Gastroenterology Research and Practice, vol. 2014, Article ID 457101, 7 pages, 2014.

Y. Ezoe, M. Muto, T. Horimatsu et al., “Efficacy of preventive endoscopic balloon dilation for esophageal stricture after endoscopic resection,” Journal of Clinical Gastroenterology, vol. 45, no. 3, pp. 222–227, 2011.

Y. Yoda, T. Yano, K. Kaneko et al., “Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer,” Surgical Endoscopy, vol. 26, no. 10, pp. 2877–2883, 2012.

H. K. Na, K. D. Choi, J. Y. Ahn et al., “Outcomes of balloon dilation for the treatment of strictures after endoscopic submucosal dissection compared with peptic strictures,” Surgical Endoscopy, vol. 27, no. 9, pp. 3237–3246, 2013.

S. Abe, P. G. Iyer, I. Oda, N. Kanai, and Y. Saito, “Approaches for stricture prevention after esophageal endoscopic resection,” Gastrointestinal Endoscopy, vol. 86, no. 5, pp. 779–791, 2017.

N. Yamaguchi, H. Isomoto, T. Nakayama et al., “Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma,” Gastrointestinal Endoscopy, vol. 73, no. 6, pp. 1115–1121, 2011.

M. Kataoka, S. Anzai, T. Shirasaki et al., “Efficacy of short period, low dose oral prednisolone for the prevention of stricture after circumferential endoscopic submucosal dissection (ESD) for esophageal cancer,” Endoscopy International Open, vol. 03, no. 02, pp. E113–E117, 2015.

H. Sato, H. Inoue, Y. Kobayashi et al., “Control of severe strictures after circumferential endoscopic submucosal dissection for esophageal carcinoma: oral steroid therapy with balloon dilation or balloon dilation alone,” Gastrointestinal Endoscopy, vol. 78, no. 2, pp. 250–257, 2013.

T. Iizuka, D. Kikuchi, S. Hoteya, and M. Kaise, “Effectiveness of modified oral steroid administration for preventing esophageal stricture after entire circumferential endoscopic submucosal dissection,” Diseases of the Esophagus, pp. 1–6, 2018.

G. Zhou, F. Yuan, J. Cai et al., “Efficacy of prednisone for prevention of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma,” Thoracic Cancer, vol. 8, no. 5, pp. 489–494, 2017.

J.-P. Ratone, E. Boriesa, F. Caillol et al., “Oral steroid prophylaxis is effective in preventing esophageal strictures after large endoscopic resection,” Annals of Gastroenterology, vol. 30, no. 1, pp. 62–66, 2017.

N. Yamaguchi, H. Isomoto, S. Shikuwa et al., “Effect of oral prednisolone on esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: a case report,” Digestion, vol. 83, no. 4, pp. 291–295, 2011.

H. Isomoto, N. Yamaguchi, T. Nakayama et al., “Management of esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma,” BMC Gastroenterology, vol. 11, pp. 1–7, 2011.

N. C. Klein, C. H. Go, and B. A. Cunha, “Infections associated with steroid use,” Infectious Disease Clinics of North America, vol. 15, pp. 423–432, 2001.

J. F. Oliveira, E. G. H. Moura, W. M. Bernardo et al., “Prevention of esophageal stricture after endoscopic submucosal dissection: a systematic review and meta-analysis,” Surgical Endoscopy, vol. 30, no. 7, pp. 2779–2791, 2016.

S. Tasaka and H. Tokuda, “Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies,” Journal of Infection and Chemotherapy, vol. 18, no. 6, pp. 793–806, 2012.

A. H. Limper, K. S. Knox, G. A. Sarosi et al., “An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 1, pp. 96–128, 2011.

T. Ishida, Y. Morita, N. Hoshi et al., “Disseminated nocardiosis during systemic steroid therapy for the prevention of esophageal stricture after endoscopic submucosal dissection,” Digestive Endoscopy, vol. 27, no. 3, pp. 388–391, 2015.

A. E. Stuck, C. E. Minder, and F. J. Frey, “Risk of infectious complications in patients taking glucocorticosteroids,” Reviews of Infectious Diseases, vol. 11, no. 6, pp. 954–963, 1989.

S. Werner and R. Grose, “Regulation of wound healing by growth factors and cytokines,” Physiological Reviews, vol. 83, no. 3, pp. 835–870, 2003.

K. W. Ashcraft and T. M. Holder, “The expeimental treatment of esophageal strictures by intralesional steroid injections,” The Journal of Thoracic and Cardiovascular Surgery, vol. 58, no. 5, pp. 685–691, 1969.

T. M. Holder, K. W. Ashcraft, and L. Leape, “The treatment of patients with esophageal strictures by local steroid injections,” Journal of Pediatric Surgery, vol. 4, no. 6, pp. 646–653, 1969.

R. Kochhar and G. K. Makharia, “Usefulness of intralesional triamcinolone in treatment of benign esophageal strictures,” Gastrointestinal Endoscopy, vol. 56, no. 6, pp. 829–834, 2002.

J. I. Ramage Jr., A. Rumalla, T. H. Baron et al., “A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures,” American Journal of Gastroenterology, vol. 100, no. 11, pp. 2419–2425, 2005.

E. Altintas, S. Kacar, B. Tunc et al., “Intralesional steroid injection in benign esophageal strictures resistant to bougie dilation,” Journal of Gastroenterology and Hepatology, vol. 19, no. 12, pp. 1388–1391, 2004.

H. Isomoto, N. Yamaguchi, T. Nakayama et al., “Management of esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma,” BMC Gastroenterology, vol. 11, no. 46, 2011.

K. Nonaka, M. Miyazawa, S. Ban et al., “Different healing process of esophageal large mucosal defects by endoscopic mucosal dissection between with and without steroid injection in an animal model,” BMC Gastroenterology, vol. 13, no. 1, 2013.

N. Hanaoka, R. Ishihara, Y. Takeuchi et al., “Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer: a controlled prospective study,” Endoscopy, vol. 44, no. 11, pp. 1007–1011, 2012.

H. Takahashi, Y. Arimura, S. Okahara et al., “A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection,” BMC Gastroenterology, vol. 15, no. 1, 2015.

M. Xu, Q. Li, C. Zhang, J. Hu, and Y. Chu, “intralesional steroid injection to prevent esophageal stricture after endoscopic submucosal dissection of lesion no less than a half of circumference,” Gastrointestinal Endoscopy, vol. 83, p. 5S, 2016.

Y. Nagami, M. Shiba, K. Tominaga et al., “Locoregional steroid injection prevents stricture formation after endoscopic submucosal dissection for esophageal cancer: a propensity score matching analysis,” Surgical Endoscopy, vol. 30, no. 4, pp. 1441–1449, 2016.

Y. Nagami, M. Ominami, M. Shiba et al., “Prediction of esophageal stricture in patients given locoregional triamcinolone injections immediately after endoscopic submucosal dissection,” Digestive Endoscopy, vol. 30, no. 2, pp. 198–205, 2018.

Y. Tsujii, Y. Hayashi, N. Kawai et al., “Safety and efficacy of steroid injection therapy for preventing esophageal stricture after endoscopic submucosal dissection(ESD),” Gastrointestinal Endoscopy 2016, vol. 83, p. 5S, 2016.

Y. Tsujii, Y. Hayashi, N. Kawai et al., “Risk of perforation in balloon dilation associated with steroid injection for preventing esophageal stricture after endoscopic submucosal dissection,” Endoscopy International Open, vol. 05, no. 07, pp. E573–E579, 2017.

T. Yamashina, N. Uedo, M. Fujii et al., “Delayed perforation after intralesional triamcinolone injection for esophageal stricture following endoscopic submucosal dissection,” Endoscopy, vol. 45, no. 2, p. E92, 2013.

Y. Nagami, M. Shiba, M. Ominami et al., “Single locoregional triamcinolone injection immediately after esophageal endoscopic submucosal dissection prevents stricture formation,” Clinical and Translational Gastroenterology, vol. 8, p. e75, 2017.

H. Furuhashi, T. R. Ohya, Y. Hara, A. Dobashi, K. Goda, and K. Sumiyama, “Clinical validity and cost effectiveness of prophylactic topical steroid injection to prevent stricture after widespread esophageal endoscopic submucosal dissection,” Gastrointestinal Endoscopy, vol. 85, no. 5S, 2017.

H. Mori, K. Rafiq, H. Kobara et al., “Steroid permeation into the artificial ulcer by combined steroid gel application and balloon dilatation: prevention of esophageal stricture,” Journal of Gastroenterology and Hepatology, vol. 28, no. 6, pp. 999–1003, 2013.

F. Yang, D. Ma, Q.-C. Cai, and Z.-S. Li, “Esophageal strictures after extensive endoscopic submucosal dissection: Steroid gel application, the ideal choice?” Journal of Gastroenterology and Hepatology, vol. 28, no. 12, pp. 1795–1797, 2013.

S. Ono, M. Fujishiro, S. Kodashima et al., “High-dose dexamethasone may prevent esophageal stricture after endoscopic submucosal dissection,” Clinical Journal of Gastroenterology, vol. 3, no. 3, pp. 155–158, 2010.

J. Nakamura, T. Hikichi, M. Sato et al., “Efficacy and safety of steroid pulse therapy to prevent after endoscopic submucosal dissection stenosis for early esophageal cancer,” Gastrointestinal Endoscopy, vol. 81, p. AB525, 2015.

J. Nakamura, T. Hikichi, K. Watanabe, M. Sato, K. Obara, and H. Ohira, “Feasibility of short-period, high-dose intravenous methylprednisolone for preventing stricture after endoscopic submucosal dissection for esophageal cancer:a preliminary study,” Gastroenterology Research and Practice, 2017.

K. Shibagaki, N. Ishimura, N. Oshima et al., “Esophageal triamcinolone acetonide-filling method: A novel procedure to prevent stenosis after extensive esophageal endoscopic submucosal dissection (with videos),” Gastrointestinal Endoscopy, vol. 87, pp. 380–389, 2018.

M. Jalali and A. Bayat, “Current use of steroids in management of abnormal raised skin scars,” The Surgeon, vol. 5, no. 3, pp. 175–180, 2007.

W. Wang and Z. Ma, “Steroid administration is effective to prevent strictures after endoscopic esophageal submucosal dissection: a network meta-analysis,” Medicine (United States), vol. 94, pp. 1–9, 2015.

J. Yang, X. Wang, Y. Li et al., “Efficacy and safety of steroid in the prevention of esophageal stricture after endoscopic submucosal dissection: A network meta-analysis,” Journal of Gastroenterology and Hepatology, 2018.

T. Mizutani, M. Tanaka, J. Eba et al., “A Phase III study of oral steroid administration versus local steroid injection therapy for the prevention of esophageal stricture after endoscopic submucosal dissection (JCOG1217, Steroid EESD P3),” Japanese Journal of Clinical Oncology, vol. 45, no. 11, pp. 1087–1090, 2015.

K. Kawaguchi, H. Kurumi, Y. Takeda, K. Yashima, and H. Isomoto, “Management of strictures after endoscopic submucosal dissection for superficial esophageal cancer,” Annals of Translational Medicine, vol. 5, p. 184, 2017.

T. Kadota, T. Yano, T. Kato et al., “Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma,” Endoscopy International Open, vol. 04, no. 12, pp. E1267–E1274, 2016.

W. J. Lee, H.-Y. Jung, D. H. Kim et al., “Intralesional steroid injection to prevent stricture after near-circumferential endosopic submucosal dissection for superficial esophageal cancer,” Clinical Endoscopy, vol. 46, no. 6, pp. 643–646, 2013.